Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023

×

錯誤訊息

  • Notice：Undefined property: stdClass::$ds_changed 於 eval() (/var/www/7/modules/php/php.module(80) : eval()'d code 中的第 16 行)。
  • Notice：Undefined property: stdClass::$ss_search_api_url 於 eval() (/var/www/7/modules/php/php.module(80) : eval()'d code 中的第 20 行)。
  • Notice：Undefined property: stdClass::$tm_title 於 eval() (/var/www/7/modules/php/php.module(80) : eval()'d code 中的第 20 行)。

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
星期三, 十二月 13, 2023
Information
Tags: 
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Webcast, PAH, Patient, GOSS, Pulmonary hypertension, Orthostatic hypertension, CSF1R
Geotags: 
CALIFORNIA, UNITED STATES, NORTH AMERICA, BIO
⚠ partially generated by AI ↴
Stock Symbol: 
NASDAQ:GOSS
摘要
Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients.
  • Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension.
  • The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com .
  • Alternatively, the conference call may be accessed through the following:
    A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com .


Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients. Seralutinib is a tyrosine kinase inhibitor targeting PDGFRα/β, CSF1R, and c-KIT, specifically designed to be delivered via dry powder inhaler for the treatment of pulmonary hypertension.

The live audio webcast may be accessed through the “Events / Presentations” page in the “Investors” section of the Company's website at www.gossamerbio.com. Alternatively, the conference call may be accessed through the following:

Date / Time: December 18, 8:30 am EST

Dial-in Number: 1-800-285-6670

Conference Reference: Gossamer Bio – Torrey OLE Update

Live Webcast: https://edge.media-server.com/mmc/p/pqeu4vsm

A replay of the audio webcast will be available for 30 days on the “Investors” section of the Company's website, www.gossamerbio.com.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.

Copyright: 
Copyright Business Wire 2023